Phathom Pharmaceuticals (PHAT) Non-Current Debt (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Non-Current Debt of $164.6 million for Q2 2026, down 19.77% year-over-year from $205.1 million in Q2 2025, and up 0.56% quarter-over-quarter from $163.7 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Non-Current Debt (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Non-Current Debt for 8 consecutive years, with $164.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Debt fell 19.77% year-over-year to $164.6 million; the TTM figure through Jun 2026 stood at $164.6 million (down 19.77% YoY), while the FY2025 annual figure was $209.1 million, up 3.81% from the prior year.
- Non-Current Debt climbed to $164.6 million in Q2 2026 per PHAT's latest filing, from $163.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $209.1 million in Q4 2025 and bottomed at $91.0 million in Q1 2022.
- Historically, Non-Current Debt has averaged $147.6 million across 5 years, with a median of $156.3 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Debt jumped 155.82% — and 2026, when it fell 19.77%.
- Phathom Pharmaceuticals' Non-Current Debt stood at $95.3 million in 2022, then jumped by 44.69% to $137.8 million in 2023, then soared by 46.12% to $201.4 million in 2024, then rose by 3.81% to $209.1 million in 2025, then slipped by 21.28% to $164.6 million in 2026.
- Business Quant data shows PHAT's Non-Current Debt at $164.6 million in Q2 2026, $163.7 million in Q1 2026, and $209.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 164.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 164.59 Mn |
| Mar 31, 2026 | 163.68 Mn |
| Dec 31, 2025 | 209.09 Mn |
| Sep 30, 2025 | 207.09 Mn |
| Jun 30, 2025 | 205.14 Mn |
| Mar 31, 2025 | 203.25 Mn |
| Dec 31, 2024 | 201.41 Mn |
| Sep 30, 2024 | 175.73 Mn |
| Jun 30, 2024 | 174.42 Mn |
| Mar 31, 2024 | 149.02 Mn |
| Dec 31, 2023 | 137.84 Mn |
| Sep 30, 2023 | 99.26 Mn |
| Jun 30, 2023 | 97.81 Mn |
| Mar 31, 2023 | 96.64 Mn |
| Dec 31, 2022 | 95.26 Mn |
| Sep 30, 2022 | 93.88 Mn |
| Jun 30, 2022 | 92.43 Mn |
| Mar 31, 2022 | 91.04 Mn |
| Dec 31, 2021 | 89.67 Mn |
| Sep 30, 2021 | 88.31 Mn |